FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2118344630> ?p ?o ?g. }

• W2118344630 endingPage "R255" @default.
• W2118344630 startingPage "R255" @default.
• W2118344630 abstract "Dasatinib is a potent, multi-targeted kinase inhibitor that was recently approved for treatment of chronic myelogenous leukemia resistant to imatinib. To aid the clinical development of dasatinib in prostate cancer, we utilized preclinical models to identify potential molecular markers for patient stratification and efficacy monitoring.Using gene expression profiling, we first identified 174 genes whose expression was highly correlated with in vitro sensitivity of 16 cell lines and, thus, considered as candidate efficacy predictive markers. Among these are important prostatic cell lineage markers, cytokeratin 5, androgen receptor and prostate specific antigen. Our results indicate that 'basal type' cell lines with high expression of cytokeratin 5 and low expression of androgen receptor or prostate specific antigen are sensitive to dasatinib. To identify markers as surrogates for biological activity, we treated cell lines with dasatinib and identified genes whose expression was significantly modulated by the drug. Ten genes, including that encoding urokinase-type plasminogen activator (uPA), were found to not only be potential efficacy markers but also to have reduced expression upon dasatinib treatment. The down-regulation of uPA by dasatinib was drug-specific and correlated with the sensitivity of cell lines to dasatinib. Furthermore, EphA2, a target of dasatinib, was found to be a sensitivity biomarker.Using the gene expression profiling approach and preclinical models, we have identified prostatic biomarkers that are associated with sensitivity to dasatinib. This study has provided a basis for clinical evaluation of a potential dasatinib efficacy signature in prostate cancer." @default.
• W2118344630 created "2016-06-24" @default.
• W2118344630 creator A5029190950 @default.
• W2118344630 creator A5041785188 @default.
• W2118344630 creator A5044389509 @default.
• W2118344630 creator A5050616688 @default.
• W2118344630 creator A5050756282 @default.
• W2118344630 creator A5088868208 @default.
• W2118344630 creator A5089007791 @default.
• W2118344630 date "2007-01-01" @default.
• W2118344630 modified "2023-10-12" @default.
• W2118344630 title "Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: Rationale for patient selection and efficacy monitoring" @default.
• W2118344630 cites W1534435601 @default.
• W2118344630 cites W1740737174 @default.
• W2118344630 cites W1963592300 @default.
• W2118344630 cites W1988698939 @default.
• W2118344630 cites W1991541715 @default.
• W2118344630 cites W1994309500 @default.
• W2118344630 cites W2003955264 @default.
• W2118344630 cites W2003973314 @default.
• W2118344630 cites W2023097049 @default.
• W2118344630 cites W2026279585 @default.
• W2118344630 cites W2031347168 @default.
• W2118344630 cites W2036988959 @default.
• W2118344630 cites W2039057614 @default.
• W2118344630 cites W2044858733 @default.
• W2118344630 cites W2053191626 @default.
• W2118344630 cites W2061837329 @default.
• W2118344630 cites W2062099953 @default.
• W2118344630 cites W2064117760 @default.
• W2118344630 cites W2066000490 @default.
• W2118344630 cites W2078400569 @default.
• W2118344630 cites W2089531514 @default.
• W2118344630 cites W2090408635 @default.
• W2118344630 cites W2092606584 @default.
• W2118344630 cites W2094161067 @default.
• W2118344630 cites W2096205264 @default.
• W2118344630 cites W2097255042 @default.
• W2118344630 cites W2101257013 @default.
• W2118344630 cites W2109850844 @default.
• W2118344630 cites W2113962581 @default.
• W2118344630 cites W2114457864 @default.
• W2118344630 cites W2118210330 @default.
• W2118344630 cites W2120292596 @default.
• W2118344630 cites W2122147062 @default.
• W2118344630 cites W2133148545 @default.
• W2118344630 cites W2135833373 @default.
• W2118344630 cites W2150926065 @default.
• W2118344630 cites W2153454576 @default.
• W2118344630 cites W2154027407 @default.
• W2118344630 cites W2155498341 @default.
• W2118344630 cites W2157840751 @default.
• W2118344630 cites W2159400887 @default.
• W2118344630 doi "https://doi.org/10.1186/gb-2007-8-11-r255" @default.
• W2118344630 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2258199" @default.
• W2118344630 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18047674" @default.
• W2118344630 hasPublicationYear "2007" @default.
• W2118344630 type Work @default.
• W2118344630 sameAs 2118344630 @default.
• W2118344630 citedByCount "74" @default.
• W2118344630 countsByYear W21183446302012 @default.
• W2118344630 countsByYear W21183446302013 @default.
• W2118344630 countsByYear W21183446302014 @default.
• W2118344630 countsByYear W21183446302015 @default.
• W2118344630 countsByYear W21183446302016 @default.
• W2118344630 countsByYear W21183446302017 @default.
• W2118344630 countsByYear W21183446302018 @default.
• W2118344630 countsByYear W21183446302019 @default.
• W2118344630 countsByYear W21183446302020 @default.
• W2118344630 countsByYear W21183446302021 @default.
• W2118344630 countsByYear W21183446302022 @default.
• W2118344630 countsByYear W21183446302023 @default.
• W2118344630 crossrefType "journal-article" @default.
• W2118344630 hasAuthorship W2118344630A5029190950 @default.
• W2118344630 hasAuthorship W2118344630A5041785188 @default.
• W2118344630 hasAuthorship W2118344630A5044389509 @default.
• W2118344630 hasAuthorship W2118344630A5050616688 @default.
• W2118344630 hasAuthorship W2118344630A5050756282 @default.
• W2118344630 hasAuthorship W2118344630A5088868208 @default.
• W2118344630 hasAuthorship W2118344630A5089007791 @default.
• W2118344630 hasBestOaLocation W21183446301 @default.
• W2118344630 hasConcept C121608353 @default.
• W2118344630 hasConcept C126322002 @default.
• W2118344630 hasConcept C143998085 @default.
• W2118344630 hasConcept C2777583451 @default.
• W2118344630 hasConcept C2778729363 @default.
• W2118344630 hasConcept C2779536868 @default.
• W2118344630 hasConcept C2780192828 @default.
• W2118344630 hasConcept C502942594 @default.
• W2118344630 hasConcept C71924100 @default.
• W2118344630 hasConcept C86803240 @default.
• W2118344630 hasConceptScore W2118344630C121608353 @default.
• W2118344630 hasConceptScore W2118344630C126322002 @default.
• W2118344630 hasConceptScore W2118344630C143998085 @default.
• W2118344630 hasConceptScore W2118344630C2777583451 @default.
• W2118344630 hasConceptScore W2118344630C2778729363 @default.
• W2118344630 hasConceptScore W2118344630C2779536868 @default.
• W2118344630 hasConceptScore W2118344630C2780192828 @default.

• next